Obstacles to and opportunities for more effective peptide-based therapeutic immunization in human melanoma

• Published in: Clinics in dermatology Vol. 27; no. 6; pp. 603 - 613
• Main Authors: Ray, Swagatam, PhD, Chhabra, Arvind, PhD, Mehrotra, Shikhar, PhD, Chakraborty, Nitya G., PhD, Ribas, Antoni, MD, Economou, James, MD, PhD, Mukherji, Bijay, MD
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.11.2009
• Subjects: Antigens, Neoplasm - immunology; Cancer Vaccines - administration & dosage; Cancer Vaccines - immunology; Dermatology; Female; Forecasting; Humans; Immunization - methods; Immunization - trends; Immunohistochemistry; Male; Melanoma - immunology; Melanoma - pathology; Melanoma - therapy; Neoplasm Invasiveness - pathology; Neoplasm Staging; Peptides - administration & dosage; Peptides - immunology; Prognosis; Risk Assessment; Skin Neoplasms - immunology; Skin Neoplasms - pathology; Skin Neoplasms - therapy; T-Lymphocytes - immunology; Treatment Outcome
• ISSN: 0738-081X; 1879-1131
• DOI: 10.1016/j.clindermatol.2008.09.019

Abstract Melanoma cells can play a number of tricks to evade the host immune response. They can make themselves invisible to cells of the immune system poised to attack them, elaborate molecules that are frankly immunosuppressive, and can create a microenvironment that is hostile to cells of the immune system. Efforts are underway to institute measures that would make tumor cells more susceptible to immune attack, but these efforts have not been all that successful so far. This contribution reviews the history and the rationale of cancer vaccines, the major obstacles to peptide-based immunization, and a discussion on how to surmount them. Also included are the roles played by peripheral tolerance, low-affinity T-cell receptors, T-cell ignorance, activation-induced cell death, exhaustion of T cells and regulation of the immune response, helpless cytolytic T lymphocytes, and evasion by tumor cells.